PMID- 22675261
OWN - NLM
STAT- MEDLINE
DCOM- 20120827
LR  - 20211021
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 6
DP  - 2012
TI  - Update on the development of lurasidone as a treatment for patients with acute 
      schizophrenia.
PG  - 107-15
LID - 10.2147/DDDT.S11180 [doi]
AB  - Lurasidone is a novel benzisothiazole antipsychotic drug for the treatment of 
      schizophrenia. Of the antipsychotic drugs, lurasidone has the highest affinity 
      for the 5-hydroxytryptamine (5-HT)(7) receptor. Lurasidone also has high 
      affinities for the dopamine D(2), 5HT(2A), 5-HT(1A) and alpha(2C) adrenergic 
      receptors. Moreover, lurasidone has low affinities for the alpha(1) adrenergic, 
      histamine H(1) and muscarinic M(1) receptors. The involvement of 5-HT(7) 
      receptors in cognitive processes has been suggested by both pharmacological and 
      molecular investigations. Chronic treatment with lurasidone increases 
      neurotrophin BDNF mRNA levels in both the hippocampus (ventral and dorsal) and 
      prefrontal cortex under basal conditions or in response to an acute swim stress. 
      Lurasidone may potentiate N-methyl-D-aspartate receptor (NMDAR) function through 
      antagonistic action on 5-HT(7) receptors without a direct affinity for NMDARs. 
      These results suggest that lurasidone treatment may be a novel approach for the 
      prevention of the development of cognitive impairment in individuals who are at 
      risk for schizophrenia or related disorders involving cognitive impairment. In 
      clinical trials, treatment with lurasidone was associated with significantly 
      greater endpoint improvement versus placebo on the Positive and Negative Syndrome 
      Scale total score after 6 weeks among subjects receiving 80 or 160 mg. The most 
      frequent side effects of lurasidone were akathisia, nausea, parkinsonism, 
      dizziness and somnolence. Once-daily treatment with lurasidone at 160 mg was 
      superior to placebo based on the composite cognitive functioning measure. 
      Lurasidone treatment produced improvements in Montgomery-Asberg Depression Rating 
      Scale scores at 6 weeks that were significantly greater than placebo. A 
      limitation of this review is that the majority of the data were obtained from 
      abstracts and posters. These sources have not been subjected to the peer review 
      processes of medical journals; thus, the results presented in these forums may 
      require further quality review and subsequent revision prior to final 
      publication.
FAU - Yasui-Furukori, Norio
AU  - Yasui-Furukori N
AD  - Department of Neuropsychiatry, Hirosaki University School of Medicine, Aomori, 
      Japan. yasufuru@cc.hirosaki-u.ac.jp
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120508
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Isoindoles)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Thiazoles)
RN  - 0 (serotonin 7 receptor)
RN  - O0P4I5851I (Lurasidone Hydrochloride)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/pharmacology
MH  - Antipsychotic Agents/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/physiology
MH  - Clinical Trials as Topic
MH  - Cognition/drug effects
MH  - Humans
MH  - Isoindoles/adverse effects/pharmacology/*therapeutic use
MH  - Lurasidone Hydrochloride
MH  - Metabolomics
MH  - Receptors, N-Methyl-D-Aspartate/drug effects/physiology
MH  - Receptors, Serotonin/drug effects/physiology
MH  - Schizophrenia/drug therapy
MH  - Thiazoles/adverse effects/pharmacology/*therapeutic use
PMC - PMC3367402
OTO - NOTNLM
OT  - 5-HT7
OT  - BDNF
OT  - antipsychotic
OT  - cognition
OT  - lurasidone
OT  - schizophrenia
EDAT- 2012/06/08 06:00
MHDA- 2012/08/28 06:00
PMCR- 2012/05/08
CRDT- 2012/06/08 06:00
PHST- 2012/06/08 06:00 [entrez]
PHST- 2012/06/08 06:00 [pubmed]
PHST- 2012/08/28 06:00 [medline]
PHST- 2012/05/08 00:00 [pmc-release]
AID - dddt-6-107 [pii]
AID - 10.2147/DDDT.S11180 [doi]
PST - ppublish
SO  - Drug Des Devel Ther. 2012;6:107-15. doi: 10.2147/DDDT.S11180. Epub 2012 May 8.